Each year, HAE Canada celebrates hae day : – ) by inviting our HAE community to participate in HAE International (HAEi) ‘s annual Virtual Global Walk; a world-wide awareness initiative with the goal of improving diagnosis and care for people with HAE. Ultimately, to help create better quality of life for everyone with HAE.
Latest News
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help
A New CSL Behring Patient Support Program
We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into
Have no fear, the COVID vaccine is safe
Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this
TAKHZYRO Now Available in Alberta
We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug
TAKHZYRO: One Step Closer
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed
Terrific News for HAE Patients in Quebec
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
